Drug intelligence / Profile preview

MTX-001 EXO

Development stage: Preclinical
Lead developer: Merakris Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

MTX-001 EXO is a cell-free amniotic fluid liquid formulation developed by Merakris Therapeutics as a liquid line expansion for wound care applications. This biologic product is derived from amniotic fluid and contains a complex mixture of bioactive factors, including exosomes, cytokines, chemokines, polysaccharides, hyaluronic acid, and electrolytes. It is designed for topical or local application to support wound healing and regenerative processes. The therapeutic mechanism involves the delivery of these bioactive components to modulate biological pathways such as the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET), thereby promoting tissue repair in chronic or non-healing wounds.

Other names: MTX-001 EXO (++) RX

Beyond the preview

Go deeper on MTX-001 EXO.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTX-001 EXO.

Explore the full profile